Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gene Editing | 8 | 2024 | 229 | 2.290 |
Why?
|
| CRISPR-Cas Systems | 6 | 2024 | 362 | 2.020 |
Why?
|
| T-Lymphocytes | 13 | 2024 | 3944 | 1.350 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2024 | 714 | 0.980 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2022 | 331 | 0.750 |
Why?
|
| Streptococcus pyogenes | 1 | 2018 | 130 | 0.590 |
Why?
|
| Immunotherapy, Adoptive | 8 | 2024 | 1840 | 0.570 |
Why?
|
| Receptors, Antigen, T-Cell | 7 | 2024 | 1135 | 0.560 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2023 | 7017 | 0.470 |
Why?
|
| Cell Movement | 1 | 2022 | 2472 | 0.460 |
Why?
|
| Genomics | 1 | 2023 | 2837 | 0.400 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 2808 | 0.400 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2016 | 1367 | 0.340 |
Why?
|
| Tacrolimus | 2 | 2020 | 347 | 0.320 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2023 | 185 | 0.260 |
Why?
|
| Plasma Cells | 1 | 2024 | 196 | 0.220 |
Why?
|
| Hydrogels | 1 | 2024 | 134 | 0.220 |
Why?
|
| CD3 Complex | 1 | 2024 | 320 | 0.220 |
Why?
|
| Cell Engineering | 1 | 2023 | 35 | 0.220 |
Why?
|
| Genetic Therapy | 2 | 2021 | 1714 | 0.210 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2023 | 22 | 0.210 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2024 | 683 | 0.210 |
Why?
|
| Immunologic Memory | 1 | 2024 | 380 | 0.200 |
Why?
|
| Cytosine | 1 | 2022 | 155 | 0.190 |
Why?
|
| Killer Cells, Natural | 2 | 2024 | 965 | 0.180 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2023 | 327 | 0.180 |
Why?
|
| Burkitt Lymphoma | 1 | 2023 | 350 | 0.180 |
Why?
|
| Antigens, CD19 | 2 | 2021 | 584 | 0.180 |
Why?
|
| Genome | 1 | 2023 | 690 | 0.160 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 114 | 0.160 |
Why?
|
| PAX5 Transcription Factor | 1 | 2019 | 47 | 0.160 |
Why?
|
| Drug Resistance | 1 | 2020 | 610 | 0.160 |
Why?
|
| Adoptive Transfer | 1 | 2021 | 431 | 0.160 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 480 | 0.160 |
Why?
|
| Immune Tolerance | 1 | 2021 | 427 | 0.160 |
Why?
|
| Antigens, CD7 | 1 | 2017 | 30 | 0.140 |
Why?
|
| Interleukin-7 | 1 | 2017 | 92 | 0.140 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 1431 | 0.140 |
Why?
|
| Leukocyte Common Antigens | 1 | 2016 | 191 | 0.130 |
Why?
|
| Humans | 21 | 2024 | 270880 | 0.130 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 269 | 0.130 |
Why?
|
| NF-kappa B | 1 | 2022 | 1564 | 0.130 |
Why?
|
| Neuroblastoma | 2 | 2020 | 705 | 0.130 |
Why?
|
| Cell Line, Tumor | 5 | 2022 | 14841 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 760 | 0.120 |
Why?
|
| Interferon-gamma | 1 | 2018 | 1180 | 0.120 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 513 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 1642 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2016 | 1474 | 0.100 |
Why?
|
| Mice | 6 | 2024 | 35598 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 4480 | 0.090 |
Why?
|
| Animals | 8 | 2024 | 62051 | 0.080 |
Why?
|
| DNA Repair | 1 | 2016 | 1910 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2022 | 3557 | 0.080 |
Why?
|
| Transduction, Genetic | 2 | 2020 | 494 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2022 | 12103 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2017 | 1776 | 0.070 |
Why?
|
| Neoplasms | 2 | 2022 | 15933 | 0.060 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2023 | 1097 | 0.060 |
Why?
|
| Sepharose | 1 | 2024 | 35 | 0.060 |
Why?
|
| Hyaluronic Acid | 1 | 2024 | 152 | 0.050 |
Why?
|
| Tissue Scaffolds | 1 | 2024 | 134 | 0.050 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2022 | 12 | 0.050 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2023 | 37 | 0.050 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2023 | 59 | 0.050 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2022 | 38 | 0.050 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2022 | 138 | 0.050 |
Why?
|
| Mutation | 2 | 2021 | 15911 | 0.050 |
Why?
|
| Antigens, Neoplasm | 2 | 2020 | 1580 | 0.050 |
Why?
|
| Mice, Inbred NOD | 1 | 2024 | 897 | 0.050 |
Why?
|
| Collagen | 1 | 2024 | 726 | 0.050 |
Why?
|
| Phenotype | 2 | 2024 | 6516 | 0.050 |
Why?
|
| Disease Resistance | 1 | 2020 | 25 | 0.050 |
Why?
|
| Germany | 1 | 2020 | 123 | 0.040 |
Why?
|
| Gene Expression | 2 | 2020 | 3642 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2024 | 968 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 3919 | 0.040 |
Why?
|
| Living Donors | 1 | 2020 | 175 | 0.040 |
Why?
|
| Young Adult | 1 | 2018 | 22245 | 0.040 |
Why?
|
| Withholding Treatment | 1 | 2020 | 155 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2019 | 79 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 440 | 0.040 |
Why?
|
| Genetic Engineering | 1 | 2020 | 295 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 960 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2020 | 667 | 0.040 |
Why?
|
| Allografts | 1 | 2020 | 686 | 0.040 |
Why?
|
| Cell Survival | 1 | 2024 | 3065 | 0.040 |
Why?
|
| Transgenes | 1 | 2020 | 576 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 979 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2019 | 298 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2020 | 336 | 0.040 |
Why?
|
| Adolescent | 1 | 2018 | 32770 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 1437 | 0.040 |
Why?
|
| Gene Transfer Techniques | 1 | 2021 | 804 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 1428 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2019 | 623 | 0.040 |
Why?
|
| Graft Survival | 1 | 2020 | 1082 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 506 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 179 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2024 | 2439 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2024 | 5698 | 0.030 |
Why?
|
| Models, Biological | 1 | 2024 | 3196 | 0.030 |
Why?
|
| Adult | 2 | 2020 | 82036 | 0.030 |
Why?
|
| Transcriptome | 1 | 2024 | 1960 | 0.030 |
Why?
|
| Middle Aged | 2 | 2020 | 90382 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 1054 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 2364 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2017 | 7237 | 0.030 |
Why?
|
| Male | 3 | 2020 | 128463 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2017 | 827 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2024 | 4117 | 0.030 |
Why?
|
| Protein Binding | 1 | 2020 | 3485 | 0.030 |
Why?
|
| Female | 3 | 2020 | 149029 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 1089 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2019 | 998 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 2518 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2017 | 1723 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 4224 | 0.020 |
Why?
|
| Kidney | 1 | 2020 | 2121 | 0.020 |
Why?
|
| Cytokines | 1 | 2020 | 2826 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 3845 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2020 | 33756 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 3031 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2019 | 2767 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 5060 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2023 | 13420 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 7386 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 9042 | 0.010 |
Why?
|